Case 3: An Elderly Patient With Newly Diagnosed Myeloma
EXPERT PERSPECTIVE VIRTUAL TUMOR BOARD
Ola Landgren, MD, PhD:Let’s move on to the next case. This is an older patient with a new diagnosis of multiple myeloma, and I will ask Alfred to present this patient.
Alfred Garfall, MD:Sure. This is an 81-year-old man who visited her primary care physician for a routine physical. She complained of fatigue and confusion. She has a history of hypertension and high cholesterol that’s treated with atorvastatin and lisinopril, respectively.
Her evaluation showed severe anemia, with a hemoglobin [count] of 7.6 g/dL, hypercalcaemia [level] at 14.8 mg/dL, albumin of 3.3 g/dL, elevated beta-2-microglobulin of 6.9 mg/L, serum M-spike of 4 g/dL. Her CBC [complete blood count] showed a neutrophil count of 1400 and platelets of 155,000 mm3. Creatinine is 2.2 mg/dL, with a creatinine clearance of 38 mL/min. Her serum paraprotein that you mentionedthe serum M-spike was 4.7 g/dL. We see an IgA of 7200 [APL]. An x-ray showed osteopenia lytic lesions in the right forearm. An MRI [magnetic resonance imaging] scan showed diffuse abnormal bone marrow signal, and a bone marrow biopsy showed 60% plasma cells with t(11;14). So this is a patient with revised ISS [International Staging System] stage II disease by virtue of no high-risk cytogenetic abnormalities but still with elevated beta-2-microglobulin.
Transcript edited for clarity.
Understanding Risks and Training Needs for Outpatient Bispecific Usage
December 5th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Robert Mancini, PharmD, BCOP, FHOPA, discussed the various approved bispecific T-cell engagers and gave guidance for healthcare professionals, patients, and caregivers related to adverse event management. This is the second of 2 articles based on this event.
Read More
Hashmi Reviews Teclistamab Data for a Patient With R/R Multiple Myeloma
November 30th 2023During a Targeted Oncology™ Clinical Case Forum event in partnership with the South Carolina Oncology Society, Hamza Hashmi, MD, discusses the significance of the MajesTEC-1 of the bispecific T-cell engager teclistamab for patients with relapsed/refractory multiple myeloma.
Read More
Talquetamab Shows High Response Rates in BCMA-Pretreated RRMM
November 29th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Jonathan L. Kaufman, MD, discussed results of the MonumenTAL-1 trial of talquetamab in patients with heavily pretreated relapsed/refractory multiple myeloma. This is the first of 2 articles based on this event.
Read More
Connecting Heart Disease and Hematologic Malignancies
November 28th 2023A real-world analysis found that patients with acute coronary syndrome who were also diagnosed with a hematologic malignancy had worse survival outcomes, and patients with multiple myeloma were overrepresented in the population.
Read More
